top of page
  • Writer's pictureANPDF

Cyclo Therapeutics Media Release | December 18, 2023

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Read the full statement from Cyclo Therapeutics here:

Here is a summary of the article:


To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."

Ways to support NP-C in Australia:

10 views0 comments

Recent Posts

See All



bottom of page